DDInter1910 DDInter856
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Valdecoxib {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Valdecoxib may lead to a major life threatening interaction when taken with Iohexol